Lutetium

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Retrieved on: 
土曜日, 6月 1, 2024
Lanthanum, Comment, DOTA, GD2, Patient, Annual general meeting, McCormick Place, Cancer, DCH, Society, Therapy, Radioimmunotherapy, Lutetium, Diagnosis, MBBS, MSK, MRCP, Medical device

In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.

Key Points: 
  • In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.
  • Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys.
  • The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals.
  • Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs.

ASP Isotopes Issues Letter to Stockholders

Retrieved on: 
木曜日, 4月 11, 2024
Consensus, FDA, Nuclear energy, Uranium, Memorandum, Void coefficient, SMR, Intelligence, Prostate cancer, Isotope, ASP, Silicon, Annual report, Yoy, PET, Semiconductor, Private, DOE, Acceleration, Safety, GE HealthCare, Small modular reactor, Artificial intelligence, Coal, Nuclear Energy Institute, Exercise, Isotopes of ytterbium, NEI, Cyclotron, Laser, Radiopharmaceutical, Government, FDG, Silane, Sale, Lithium, Lutetium (177Lu) vipivotide tetraxetan, LEU, Lutetium, Radionuclide, Electronics, ASPI, Letter, Growth, Rare-earth element

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.

Key Points: 
  • WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.
  • The contract required RC14 to provide an irrevocable standby letter of credit in lieu of a deposit, which was received.
  • Our proprietary technology has proven capabilities to enrich a wide range of isotopes, including light isotopes and lighter molecules, such as silane (SiH4).
  • ASP Isotopes’ goal is to become the lowest cost and most reliable supplier of stable isotopes globally.

OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program

Retrieved on: 
木曜日, 2月 22, 2024
Principal, BioNTech, Safety, Lutetium, Patient, Prostate cancer, Survival, Disease, NYU Langone Health, Cancer, Pharmaceutical industry

ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Key Points: 
  • ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).
  • BNT316/ONC-392 is being jointly developed by BioNTech and OncoC4.
  • The trial will initially evaluate the safety of BNT316/ONC-392 in combination with lutetium (177Lu) vipivotide tetraxetan and help inform the preferred dosage.
  • The trial will assess whether the combination increases progression free survival over the current standard of care as the primary endpoint.

Globex Exploration Update on Virgin Mountain Rare Earth & Beryllium Project, Arizona, USA

Retrieved on: 
火曜日, 2月 13, 2024
Thulium, Virginity, Yttrium, GMX, Beryllium, Radioactive decay, Geo, Erbium, Niobium, Density, AAL, Terbium(III) oxide, Gadolinium, Toronto Stock Exchange, ASARCO, Ytterbium, LREE, Silver, Tantalum, Assay, Dysprosium, Wolverine, Terbium, Holmium, Virgin Mountain, Asarco, Chrysoberyl, Uranium, Beryl, Geology, Element, REE, Virgin Mountains, Lutetium, Anomaly, ICP-OES, Rare-earth element

The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.

Key Points: 
  • The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.
  • Past exploration activities for uranium and later for rare earth elements (REE) initiated in the 1940’s and ended in 1991.
  • In the 1950’s and 1960’s the Virgin Mountains Be-bearing pegmatites had been explored intensely for beryllium, but never came into production.
  • Rare Earth (REE) ± U & Th mineralization is hosted in migmate-gneiss and interlayered thin schist layers, locally also in pegmatite dikes.

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

Retrieved on: 
金曜日, 1月 5, 2024
Marketing, Regulation, Food, INN, Pandemic, Sale, Government, Physician, Research, FDA, Breast, Lung, USAN, Lutetium, Prostate cancer, DOTA-TATE, Clinical trial, Lutetium (177Lu) oxodotreotide, Ligand, RLT, Isotope, Pancreatic cancer, Prostate, Cancer, Growth, Cell, Patient, Diagnosis, Safety, Pharmaceutical industry

The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.

Key Points: 
  • The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.
  • The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.
  • “The intricate process of providing RLTs to patients within hours of production requires precision manufacturing expertise to bring these medicines to individuals who critically need them,” said Steffen Lang, President, Operations, Novartis.
  • Novartis is committed to expanding the radioligand therapy platform to shape the future of RLT as a treatment class.

Shine Technologies and Curadh MTR Announce Expanded Strategic Partnership to Advance Cancer Therapies using Terbium and Lutetium

Retrieved on: 
月曜日, 9月 11, 2023
Heart, Partnership, MTR, Radionuclide, Cancer, Nuclear medicine, Patient, Shine Technologies, Isotope, SHINE, Rare-earth element, Medical imaging, Terbium, Lutetium

VIENNA, Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, an innovator in nuclear fusion technologies, and Curadh MTR Inc. (Curadh), specialists in molecularly targeted radiation (MTR), today announced an expanded long-term supply agreement for medical isotopes that promises to reshape the landscape of cancer therapies.

Key Points: 
  • The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies.
  • This alliance promises to harness the potential of radioisotopes using Terbium and Lutetium to target and eliminate cancer cells with precision, offering renewed hope to patients and reshaping the future of cancer treatment.
  • VIENNA, Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, an innovator in nuclear fusion technologies, and Curadh MTR Inc. (Curadh), specialists in molecularly targeted radiation (MTR), today announced an expanded long-term supply agreement for medical isotopes that promises to reshape the landscape of cancer therapies.
  • "We are thrilled to expand our strategic nuclear and medical partnership with SHINE Technologies, a leader in nuclear technologies, to include potential future supply of Terbium," said Dr. Alison Armour, CEO of Curadh.

ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023

Retrieved on: 
木曜日, 6月 15, 2023
Canadian Nuclear Laboratories Research Facilities, Global production network, ITM, Society, Culture, SNMMI, MB, Molecular imaging, Radiochemistry, MBA, Research, Radiopharmaceutical, Future, Nuclear medicine, Novartis, Patient, AAA, Education minister, Lutetium, Gallium, Advanced Accelerator Applications, Therapy, BAMF, Conference, Actinium-225, Management, Pharmaceutical industry, Nursing, McCormick Place, MD

The symposium will take place on June 25, from 6:30 pm to 7:30 pm CST in McCormick Place, Lakeside Center, Room E450b.

Key Points: 
  • The symposium will take place on June 25, from 6:30 pm to 7:30 pm CST in McCormick Place, Lakeside Center, Room E450b.
  • “Particularly as the demand for radiopharmaceuticals continues to grow, we value the opportunity to bring together and share this panel’s expertise and unique insights into the clinical, scientific, and production aspects of theranostics,” commented Steffen Schuster, CEO of ITM.
  • Understanding the interdependencies of these stakeholders will help ensure the value of this critical modality for patients now and well into the future.
  • of Canadian Nuclear Laboratories, an accomplished executive with more than 25 years of broad industry experience and currently focused on further developing CNL’s actinium-225 program.

Global Rare Earth Metals Market to 2031: Rising Electric Vehicle Sector Drives Growth - ResearchAndMarkets.com

Retrieved on: 
木曜日, 6月 8, 2023
Mining, Minerals, Natural Resources, Cerium, Gadolinium, Ceramic, Construction, Neodymium, Lanthanum, Metal, Metallurgy, Electronics, Promethium, DVD, Mobile phone, Phosphor, Samarium, Erbium, Europium, Holmium, Oil lamp, Scandium, Lithium battery, Magnet, Praseodymium, Yttrium, Dysprosium, Lutetium, Growth, Glass, Terbium, Ytterbium, Thulium, Rare-earth element, Catalysis

These earth metals are classified into heavy earth metals and light earth metals.

Key Points: 
  • These earth metals are classified into heavy earth metals and light earth metals.
  • The growing trends in automobile section, electric vehicle sector and consumer electronics industry is mainly stimulating the demand and growth of worldwide rare earth metals market across the globe.
  • Among the various rare earth metals types, cerium oxide evolved as the highest contributor to the total market share of the rare earth metals market all across the globe .
  • The fluctuating costs of the rare earth metals and the high level of availability of these rare earth metals in regions like China are the factors that can hinder the growth of the global rare earth metals market.

SHINE Technologies Appoints Experienced Company Builder to Board of Directors

Retrieved on: 
水曜日, 6月 7, 2023
Morgridge Institute for Research, University, Lutetium, MBA, Public health, Tomotherapy, University of Wisconsin School of Medicine and Public Health, Shine Technologies, Anesthesiology, Faculty, Growth, Research, GE HealthCare, SHINE, San Diego State University, Nursing

JANESVILLE, Wis., June 7, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced the appointment of Dr. Frederick Robertson to the company's board of directors.

Key Points: 
  • JANESVILLE, Wis., June 7, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced the appointment of Dr. Frederick Robertson to the company's board of directors.
  • Robertson brings a wealth of experience in building companies in the medical device, life science and pharmaceutical industries.
  • He held the role of CEO and director of TomoTherapy, a producer of sophisticated X-ray-based cancer therapy equipment, until the company was acquired in 2011.
  • "This is an exciting time for SHINE as it works to make fusion-driven medical isotopes a reality," Robertson said.

Purdue Research Foundation monetizes Pluvicto royalty interests to fund further research at Purdue University

Retrieved on: 
水曜日, 4月 26, 2023
Purdue Research Park, University, Senior, Drug discovery, Boilermaker, Blue Owl Capital, Research, IP, Schwegman, Lundberg & Woessner, PRF, Cooley LLP, Lutetium, Novartis, Patient, FDA, SVB Securities, Prostate cancer, Pharmaceutical industry, Lutetium (177Lu) vipivotide tetraxetan, Chemistry, Purdue University

and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Purdue Research Foundation, a private not-for-profit institute to advance the research of Purdue University, has received more than $100 million from Owl Rock, a division of Blue Owl Capital, for a portion of its royalty interest in Pluvicto (Lutetium 177Lu vipivotide tetraxetan).

Key Points: 
  • and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Purdue Research Foundation, a private not-for-profit institute to advance the research of Purdue University, has received more than $100 million from Owl Rock, a division of Blue Owl Capital, for a portion of its royalty interest in Pluvicto (Lutetium 177Lu vipivotide tetraxetan).
  • Purdue Research Foundation secured rights to royalties from Pluvicto as a result of Purdue’s license agreement with Endocyte Corp., which was acquired by Novartis in 2018.
  • This transaction helps Purdue Research Foundation advance its mission of investing in Purdue University’s innovative technologies and supports the university’s advancement.
  • “Purdue University researchers discover and develop innovations improving the world, one of the key aspects of a land-grant university.